Burgess D S, Hastings R W, Hardin T C
College of Pharmacy, The University of Texas at Austin, 78284-6220, USA.
Clin Ther. 2000 Jan;22(1):66-75. doi: 10.1016/s0149-2918(00)87978-3.
This study assessed the pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion against clinical isolates of Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus aureus.
Because beta-lactam antibiotics exhibit time-dependent bactericidal activity and lack prolonged postantibiotic effects against many bacteria, the goal of therapy is to maintain serum drug concentrations above the minimum inhibitory concentration (MIC) for the relevant pathogen over most of the dosing interval. Continuous infusion is a mode of drug administration that can provide serum drug concentrations continuously above the MIC for most bacterial pathogens.
Twelve healthy volunteers were enrolled. Each received cefepime 2 g by intermittent bolus q12h and, on another day, was randomly assigned to receive 4 or 3 g administered by continuous infusion over 24 hours.
For the intermittent regimen, the mean (+/- SD) pharmacokinetic findings were: maximum serum concentration, 112.9 +/- 21.1 microg/mL; minimum serum concentration, 1.3 +/- 0.5 microg/mL; and half-life, 2.6 +/- 0.4 hours. For the 3- and 4-g continuous infusion regimens, steady-state serum concentrations (C(SS)) were 13.9 +/- 3.8 and 20.3 +/- 3.3 microg/mL, respectively. MICs ranged from 2 to 4, 0.125 to 8, and 2 to 8 microg/mL against P. aeruginosa, E. cloacae, and S. aureus, respectively. For the intermittent regimen, serum inhibitory titers (SITs) at 24 hours were > or = 1:2 in 46% of subjects against P. aeruginosa, 48% against E. cloacae, and 2% against S. aureus. For both continuous infusion regimens, SITs for each organism were > or = 1:2 in all subjects.
The intermittent regimen maintained serum concentrations above the MIC for P. aeruginosa and E. cloacae in > or = 92% (11/12) of subjects for > or = 70% of the dosing interval, provided the MIC was < or = 4 microg/mL. Both continuous infusion regimens provided a C(SS) above the MIC for all organisms. However, the C(SS) was > or = 4 times the MIC only if the MIC was < or = 2 microg/mL. Only the 4-g regimen provided such concentrations against isolates with an MIC of 4 microg/mL, and neither regimen provided such concentrations when the MIC was 8 microg/mL. These findings should be applied in comparative clinical studies.
本研究评估了间歇性输注和持续输注头孢吡肟对铜绿假单胞菌、阴沟肠杆菌和金黄色葡萄球菌临床分离株的药代动力学和药效学。
由于β-内酰胺类抗生素表现出时间依赖性杀菌活性,且对许多细菌缺乏延长的抗生素后效应,治疗的目标是在大部分给药间隔内将血清药物浓度维持在高于相关病原体最低抑菌浓度(MIC)的水平。持续输注是一种给药方式,可使大多数细菌病原体的血清药物浓度持续高于MIC。
招募了12名健康志愿者。每人每12小时通过间歇性推注接受2g头孢吡肟,在另一天,随机分配接受在24小时内持续输注4g或3g。
对于间歇性给药方案,平均(±标准差)药代动力学结果为:血清最高浓度,112.9±21.1μg/mL;血清最低浓度,1.3±0.5μg/mL;半衰期,2.6±0.4小时。对于3g和4g持续输注方案,稳态血清浓度(C(SS))分别为13.9±3.8和20.3±3.3μg/mL。针对铜绿假单胞菌、阴沟肠杆菌和金黄色葡萄球菌的MIC范围分别为2至4、0.125至8和2至8μg/mL。对于间歇性给药方案,24小时时血清抑菌效价(SIT)在46%的受试者中针对铜绿假单胞菌≥1:2,针对阴沟肠杆菌为48%,针对金黄色葡萄球菌为2%。对于两种持续输注方案,所有受试者中每种菌株的SIT均≥1:2。
如果MIC≤4μg/mL,间歇性给药方案在≥70%的给药间隔内使≥92%(11/12)的受试者血清浓度高于铜绿假单胞菌和阴沟肠杆菌的MIC。两种持续输注方案均使所有菌株的C(SS)高于MIC。然而,只有当MIC≤2μg/mL时,C(SS)才≥MIC的4倍。只有4g给药方案对MIC为4μg/mL的分离株提供了这样的浓度,当MIC为8μg/mL时,两种给药方案均未提供这样的浓度。这些发现应应用于比较临床研究。